Compare GROV & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GROV | CVM |
|---|---|---|
| Founded | 2016 | 1983 |
| Country | United States | United States |
| Employees | 415 | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.4M | 32.4M |
| IPO Year | N/A | 1996 |
| Metric | GROV | CVM |
|---|---|---|
| Price | $1.21 | $3.07 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $1.60 | N/A |
| AVG Volume (30 Days) | ★ 95.5K | 34.1K |
| Earning Date | 03-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $264,033.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.81 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $1.02 | $0.18 |
| 52 Week High | $1.60 | $13.48 |
| Indicator | GROV | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 38.06 | 29.54 |
| Support Level | $1.19 | $2.02 |
| Resistance Level | $1.58 | $6.75 |
| Average True Range (ATR) | 0.07 | 0.30 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 8.33 | 4.22 |
Grove Collaborative Holdings Inc is engaged in providing consumer products. It offers Cleaning accessories, Home and Pantry, Personal care products, Pets supplements and Other products. It is a sustainability oriented consumer products generator. It use connection with consumers to create and curate authentic, disruptive brands and products. Company builds natural products that perform as well as, many consumer packaged goods (CPG) brands (both conventional and natural), while being healthier for consumers and the planet.
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.